Sarepta Therapeutics (SRPT) Cash from Restructuring (2016)
Sarepta Therapeutics' (SRPT) quarterly Cash from Restructuring came in at $407000.0 in Q4 2016, up 51.3% quarter-over-quarter from $269000.0 in Q3 2016.
Sarepta Therapeutics (SRPT) Cash from Restructuring (2016) Analysis & Trends
Sarepta Therapeutics' Cash from Restructuring history runs 1 years deep, the most recent figure standing at $407000.0 for Q4 2016.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Sarepta Therapeutics | 1.69 Bn | 1.28 Bn | 622.04 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2016 | 407,000.00 |
| Sep 30, 2016 | 269,000.00 |